Cargando…
CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment
Despite the development of targeted therapies and novel inhibitors, cancer remains an undefeated disease. Resistance mechanisms arise quickly and alternative treatment options are urgently required, which may be partially met by drug combinations. Protein kinases as signaling switchboards are freque...
Autores principales: | Scheiblecker, Lisa, Kollmann, Karoline, Sexl, Veronika |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760252/ https://www.ncbi.nlm.nih.gov/pubmed/33255177 http://dx.doi.org/10.3390/ph13120418 |
Ejemplares similares
-
The role of CDK6 in cancer
por: Nebenfuehr, Sofie, et al.
Publicado: (2020) -
The Effect of CDK6 Expression on DNA Methylation and DNMT3B Regulation
por: Heller, Gerwin, et al.
Publicado: (2020) -
CDK6 and p16(INK4A) in lymphoid malignancies
por: Kollmann, Karoline, et al.
Publicado: (2013) -
CDK6 Inhibition: A Novel Approach in AML Management
por: Uras, Iris Z., et al.
Publicado: (2020) -
c-JUN prevents methylation of p16INK4a (and Cdk6): the villain turned bodyguard
por: Kollmann, Karoline, et al.
Publicado: (2011)